Astrocytoma Latest Advances

Synergistic action of JNK activation and BChE inhibition: a novel anti- glioblastoma compound with neuroprotective profile.

Journal: Future medicinal chemistry

Published: April 15, 2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.

Journal: Oncoimmunology

Published: April 14, 2026

Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma.

Journal: ACS nano

Published: April 13, 2026

Biotin-Decorated Inulin-Based Polymeric Micelles Unveil Their Dual-Targeting Ability for the Potential Treatment of Glioblastoma Multiforme through the In Vitro and In Vivo Investigations.

Journal: Molecular pharmaceutics

Published: April 13, 2026

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Journal: Journal of medicinal chemistry

Published: April 13, 2026

Corrigendum to: Contralateral neurofluid dynamics predict survival in IDH wild-type glioblastoma: A DTI-ALPS and free water imaging study.

Journal: Neuro-oncology

Published: April 12, 2026

Biomimetic nanocarriers as advanced drug delivery strategies in neurological disorders.

Journal: Expert opinion on drug delivery

Published: April 11, 2026

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Pharmacologic DPP-4 inhibition promotes CD8⁺ T cell metabolic fitness to enhance anti-tumor activity.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Glioblastoma with loss of H3K27me3 and EGFR exon 20 insertion: report of a case

Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology

Published: April 09, 2026

Astrocytoma Latest Advances

Find the Latest Research About Astrocytoma

Synergistic action of JNK activation and BChE inhibition: a novel anti- glioblastoma compound with neuroprotective profile.

Synergistic action of JNK activation and BChE inhibition: a novel anti- glioblastoma compound with neuroprotective profile.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.

PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.

Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma.

Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma.

Biotin-Decorated Inulin-Based Polymeric Micelles Unveil Their Dual-Targeting Ability for the Potential Treatment of Glioblastoma Multiforme through the In Vitro and In Vivo Investigations.

Biotin-Decorated Inulin-Based Polymeric Micelles Unveil Their Dual-Targeting Ability for the Potential Treatment of Glioblastoma Multiforme through the In Vitro and In Vivo Investigations.

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Corrigendum to: Contralateral neurofluid dynamics predict survival in IDH wild-type glioblastoma: A DTI-ALPS and free water imaging study.

Corrigendum to: Contralateral neurofluid dynamics predict survival in IDH wild-type glioblastoma: A DTI-ALPS and free water imaging study.

Biomimetic nanocarriers as advanced drug delivery strategies in neurological disorders.

Biomimetic nanocarriers as advanced drug delivery strategies in neurological disorders.

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.

Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling.

Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling.

Pharmacologic DPP-4 inhibition promotes CD8⁺ T cell metabolic fitness to enhance anti-tumor activity.

Pharmacologic DPP-4 inhibition promotes CD8⁺ T cell metabolic fitness to enhance anti-tumor activity.

Glioblastoma with loss of H3K27me3 and EGFR exon 20 insertion: report of a case

Glioblastoma with loss of H3K27me3 and EGFR exon 20 insertion: report of a case